Cardiovascular adverse events (CV AEs) are rare, but potentially serious complications of immune checkpoint inhibitor (ICI) therapy. The most severe manifestation is myocarditis which can lead to heart failure, arrhythmias, and sudden cardiac death. Clinicians must recognize the common symptoms and diagnostic studies as well as their limitations to initiate early intervention. The optimal management of cardiotoxicity generally involves cessation of the ICI, early initiation of steroids, and secondary immunomodulatory treatments in refractory cases. As the use of ICIs continues to grow, our understanding of CV AEs will continue to evolve to effectively monitor and treat patients.

ABSTRACT

Immune checkpoint inhibitor (ICI) associated cardiovascular adverse events (CVAEs) have become more frequent with the growing use of cancer immunotherapy. CVAEs include a wide spectrum of diseases such as myocarditis, pericarditis, heart failure, arrhythmias, coronary artery disease, and hypertension. The induction of cardiovascular side effects by ICI use is hypothesized to occur due to inflammation and immune dysregulation of normal tissue in response to immunotherapy. Management of ICI-associated CVAEs mitigates an overactive immune response by utilizing steroids, immunomodulatory drugs and hemodynamic stabilization. However, few controlled studies on the cardiovascular safety of ICIs exist and treatment of their side effects are mostly from limited case series. Our review seeks to provide the most recent understanding of ICI-associated CVAEs and their management.

Keywords: CTLA-4; Immune checkpoint inhibitor; Myocarditis; PD-1; PD-L1

INTRODUCTION

Despite great advances in medicine, cancer continues to be one of the leading causes of death in developed countries. Recently, immunotherapy has been used with great success in previously resistant cancers. The idea of weaponizing the native immune system to
Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Conflict of Interest
The authors have no financial conflicts of interest.

Data Sharing Statement
The data generated in this study is available from the corresponding author(s) upon reasonable request.

Author Contributions
Conceptualization: Zarifa A, Kim JW, Kim PY; Data curation: Zarifa A, Kim JW, Lopez-Mattei J, Palaskas N, Kim PY; Formal analysis: Zarifa A, Kim JW, Kim PY; Funding acquisition: Zarifa A, Kim JW, Kim PY; Methodology: Zarifa A, Kim JW, Kim PY; Project administration: Zarifa A, Kim JW, Kim PY; Resources: Zarifa A, Kim JW, Kim PY; Software: Zarifa A, Kim JW, Kim PY; Supervision: Zarifa A, Kim JW, Kim PY; Validation: Zarifa A, Kim JW, Kim PY; Visualization: Zarifa A, Kim JW, Kim PY; Writing - original draft: Zarifa A, Kim JW, Kim PY; Writing - review & editing: Zarifa A, Kim JW, Lopez-Mattei J, Palaskas N, Iliescu C, Kim PY.

MECHANISMS

The native immune system uses various suppressive molecules and receptors to maintain normal T-lymphocyte function while preventing autoimmunity. Normally, T cells can identify non-self-antigens presented by antigen presenting cells (APCs) via costimulatory receptor B7 to the costimulatory receptor CD28 on T cells, leading to the activation of an immune response. A coinhibitory receptor on the T cells known as CTLA-4 inhibits the T cells and down-regulates the immune response. CTLA-4 has a higher affinity for costimulatory receptor B7 on APCs than the T cell costimulatory receptor CD28.

Tumor cells escape immune surveillance by utilizing these immune checkpoints. These specific checkpoints inhibit the activation of T cells through CTLA-4 and downregulate tumor cell apoptosis and conversion to regulatory T cells by binding of PD-1 and PD-L1 (Figure 1A). Due to the role of PD-L1 in B7 inhibition, there is also a shared characteristic between CTLA-4 and PD-1.

These immune checkpoints have been identified as targets to remove the inhibition of antitumor T cell responses. ICIs work mainly by binding and inhibiting these receptors, enabling activated immune responses against tumor cells (Figure 1B).

ICI induced cardiotoxicities are likely caused by the deactivation of CTLA-4 and PD-1, which are important in inhibiting T cell response in the cardiac muscle. Usually, these receptors suppress inflammation and prevent cardiac muscle injury associated with inflammatory processes.\(^5\)

In animal models, CTLA-4 deficient mice develop multi-organ lymphoproliferative diseases within a few weeks of life, including T cell myocarditis.\(^5\) Severe dilated cardiomyopathy with
troponin autoantibodies were found after knocking out PD-1 receptors in mice. Another study evaluated the combination of anti CTLA-4 and anti PD-1 agents in cynomolgus monkeys. These agents stimulated CD4+ and CD8+ T cell infiltration of the monkeys’ hearts. These animal studies suggest the important role of checkpoint receptors in regulating autoimmune responses in the heart and help to identify myocardial immune cell infiltration.

Similarly, investigations in humans have also revealed decreased thresholds for stimulation of T-cells to self-antigens in the heart. Endomyocardial biopsy specimens have shown myocardial T cell infiltration with immunohistochemical staining positive for PD-1 and PD-L1. Johnson et al. also found a potentiation of T cells targeting an antigen shared by both the heart and tumor. When T cell receptor sequencing of complementarity-determining region 3 (CDR3) on biopsies from the tumor, heart, and skeletal muscle specimens was performed, there were similar expression of muscle-specific transcripts and high-frequency T cell receptor sequences. The similarity of these tissue histopathologic findings seemed to suggest that T cells may respond to a common presenting antigen in different tissues possibly leading to the development of systemic autoimmune response.

ICIs have been found to play an important role in atherogenesis and coronary regulation. In animal studies, PD-1 has been found to promote the regression of proatherogenic T cell responses. Investigators have found that PD-1 knockout mice develop larger atherosclerotic lesions compared to wild type controls. This might be due to the ICIs effect on the regulation of proatherogenic T cell immunity by T cell activation causing increased production of interferon γ and tumor necrosis factor α leading to an increased risk of coronary thrombosis.

Human histologic studies of coronary vasculature have found differences of immune checkpoint expression in patients with coronary artery disease (CAD). Examination by flow

---

Figure 1. (A) Mechanism used by the tumor cells to evade the immune system. (B) Mechanism immune checkpoint inhibitors use to inhibit the tumor cells from evading the immune system. ACP = antigen presenting cells; CTLA-4 = cytotoxic T-lymphocyte-associated antigen 4; MHC = major histocompatibility complex; PD-1 = programmed cell death receptor-1; PD-L1 = programmed cell death ligand-1; TCR = T-cell receptor.
*Created with BioRender.com.
cytometry on 76 patients with CAD and 25 patients without CAD found decreased expression of PD-1 and PD-L1 on peripheral mononuclear cells in the patients with CAD. Furthermore, the investigators found the expression of these receptors was remarkably low on T cells and myeloid dendritic cells in patients with CAD when compared to controls. These findings suggest the role of PD-1 and PD-L1 in the regulation of proinflammatory atherogenic signaling.

The pathophysiology of other ICI-associated CVAEs, such as hypertension is less clear. A potential mechanism may be related to the upregulation of T-regulatory cells. ICI inhibition allows the native immune system to be activated leading to increased systemic inflammation. Chronic arterial inflammation may contribute to arterial stiffness leading to hypertension in these patients.

**CARDIAC TOXICITY OF IMMUNE CHECKPOINT INHIBITORS MANIFESTATIONS**

**Myocarditis/cardiomyopathy**

Myocarditis presents on a spectrum ranging from mild to severe disease. It can vary from asymptomatic elevations in cardiac biomarkers to symptoms suggestive of an acute coronary syndrome, heart failure exacerbation, or severe decompensation with multi-system injury leading to cardiogenic shock and death. The classification of myocarditis follows the clinical practice guidelines for the management of irAEs according to the American Society of Clinical Oncology.

The time to presentation of symptoms from receiving therapy varies, but median latency between receiving ICIs and developing myocarditis has been reported to be approximately 17 days (range, 13–64 days). However, there have been reports of myocarditis developing beyond 32 weeks after starting treatment.

Although traditional cardiac risk factors have not been clearly linked to the increased development of ICI-associated myocarditis, limited studies have shown that diabetes mellitus (DM), obstructive sleep apnea (OSA) and elevated body mass index (BMI) may lead to worse outcomes particularly in patients receiving combination therapy. There is conflicting evidence regarding previous cardiovascular disease as a potential risk factor for developing myocarditis. In a small case series of 24 patients, there was no clear cardiovascular disease or cancer-type predisposing patients to myocarditis. However, in a case series of 8 patients with myocarditis, 5 had cardiovascular disease before receiving ICIs.

The incidence of ICI-associated myocarditis is reported to be approximately 1–2%. In a registry derived from 8-centers, the overall incidence of myocarditis after ICI therapy was ~1% with approximately 0.5% with a major adverse cardiovascular event (MACE). Most of the reported myocarditis cases involved anti-PD-1 therapy with 1.3% using pembrolizumab and 0.4–0.6% with nivolumab use. The combination therapy of anti-PD-1/anti-CTLA-4 has been reported with even higher prevalence of myocarditis (2.4%) and has also been shown to present with more severe cases of myocarditis. In a study comparing the combination of nivolumab and ipilimumab versus single agent nivolumab, the rates of severe myocarditis were 0.27% vs. 0.06%, respectively. The low incidence and high mortality observed in myocarditis compared to other immune-related AEs may be due to the difficulty in diagnosis of myocarditis and the possibility of reporting bias.

https://e-kcj.org

https://doi.org/10.4070/kcj.2021.0089
Myocarditis is often reported with other irAE such as myositis (25%) and myasthenia gravis (10–41%). Due to this crossover, patients with ICI induced myositis or myasthenia gravis are recommended to be evaluated for ICI-induced myocarditis.

**Pericarditis/pericardial effusion**

After ICI initiation, patients can develop pericardial effusions with or without pericarditis. ICIs have been reported to cause persistent pericardial and pleural effusions. In a study at MD Anderson Cancer Center, 1075 patients received ICI treatment between 2015–2017 with baseline echocardiograms demonstrating no pericardial effusions. After initiation of treatment, 78 patients (7.3%) developed pericardial effusions. These patients were found to have higher rates of mortality compared to those who didn’t develop pericardial effusions, 58% versus 35%, respectively. A lower body surface area, history of heart failure, elevated troponin levels, low platelet counts, and hyperlipidemia were independent risk factors found to be significantly associated with a higher rates of pericardial effusion development.

The presence of a pericardial effusion is one of the supporting diagnostic criteria for myocarditis per the 2013 guidelines of the European Society of Cardiology. ICI-associated pericardial effusions may be due to underlying myopericarditis however, it is well known that many malignancies, especially lung, breast, and lymphomas, may independently be associated with pericardial effusions. Hence, patients with new or progressing pericardial effusions should be evaluated for ICI-induced myocarditis, which require additional diagnostic evaluations for confirmation.

**Arrhythmias/heart block**

Arrhythmia and heart conduction abnormalities are common AEs of ICIs; they include atrial fibrillation, ventricular tachyarrhythmias, and atrioventricular conduction disorders. Other electrocardiographic findings from ICI therapy include PR interval prolongation, and right or left bundle branch block. ICI-associated conduction abnormalities can be attributed to coexisting myocarditis due to immune cell infiltration in the conduction nodes, suggestive of T-cell-mediated cytotoxicity. This may not explain all cases of conduction abnormalities as was demonstrated in another study showing conduction disease without concomitant myocarditis in 13% of patients receiving ICI treatment.

When compared to conduction abnormalities due to other causes, ICI-associated conduction abnormalities are reported to cause worsening cardiovascular mortality (80% vs. 16%, respectively). Therefore, surveillance electrocardiograms (ECG) in patients who complain of symptoms of palpitations, dizziness, or syncope while receiving ICI treatment is recommended.

**Acute coronary syndrome/coronary spasm**

Effects of ICI treatment on coronary vasculature has also been implicated in limited reports. In a pharmacovigilance database of 820,571 patients receiving ICI therapy, 3,773 had immune related adverse events, of which 26 were reported as cardiovascular events. Among these 26 cases, 10 were reported as ACS with 4 cases of acute thrombosis seen on coronary angiography.

Inflammation of preexisting atherosclerotic disease from immune system activation has been known to trigger fibrous cap rupture, acute coronary thrombosis, and myocardial infarction. Release of pro-inflammatory cytokines also contribute to the destabilization of coronary lesions.
ICIs have also been reported to cause coronary spasm. In reported cases, after administration of ICI therapy, patients presented with chest pain on rest which improved immediately after receiving sublingual nitroglycerin, steroids, and immunomodulatory therapy. Coronary angiography demonstrated coronary spasm that resolved after intracoronary nitroglycerine injection. These patients had normal echocardiograms and no obstructive CAD. Although the exact mechanism of ICI induced coronary spasm is unknown, in the absence of atherosclerotic disease, ICIs have been postulated to cause a T cell-mediated coronary vasculitis.

**Hypertension**

ICI-associated hypertension (HTN) is a rare cardiotoxic event with few published reports. This CVAE has been noted in certain PD-1 (pembrolizumab, toripalimab, camrelizumab, sintilimab) and PD-L1 inhibitors (atezolizumab). In a phase 1 trial of pembrolizumab, 2 out of 101 patients developed HTN. In a 5-year follow-up study, only one additional case of HTN was reported. Early retrospective studies are consistent with these findings, reporting HTN in 1 out of 496 patients taking pembrolizumab, which occurred within 2 weeks of ICI therapy and resolved with systemic antihypertensive therapy. Three phase 3 trials comparing pembrolizumab vs. platinum-based chemotherapy did not document any ICI-associated HTN. The World Health Organization (WHO) global database of individual case safety reports from 1967 to 2018 revealed HTN and related end-organ damage in 198 out of 31,321 (0.63%) patients treated with ICIs.

Since 2018, recently approved PD-1 and PD-L1 inhibitors have documented higher rates of HTN. A retrospective single-center cohort study of toripalimab, camrelizumab, and sintilimab treatments found 13 out of 70 patients developed HTN. Atezolizumab was also found to have higher rates of HTN in two phase 1 trials where 11 out of 110 patients developed HTN.

**DIAGNOSIS**

The diagnosis of ICI-associated myocarditis is based on clinical presentation and diagnostic testing including laboratory studies, cardiac imaging, and endomyocardial biopsy.

Initial workup for patients with symptoms concerning for ICI-associated myocarditis should include a 12-lead ECG, serum troponin, brain natriuretic peptide (BNP), and echocardiogram. High clinical suspicion may require additional testing including cardiac catheterization with endomyocardial biopsy and/or cardiac magnetic resonance imaging (MRI).

The diagnosis of ICI-associated myocarditis in the setting of clinical symptoms with elevated cardiac biomarkers and/or new ECG findings such as frequent ventricular ectopy or heart block should also include at least one of the following criteria:

1) appropriate histopathological evidence on endomyocardial biopsy (EMB).
2) imaging features on cardiac magnetic resonance imaging (CMR) by Lake Louise Criteria.
3) new-onset wall motion abnormalities (WMAs) on echocardiography in the lack of other clear etiologies such as obstructive CAD.

**Laboratory studies**

Myocarditis is often initially suspected by disproportionate elevations in cardiac serum biomarkers. Although cardiac biomarkers are not highly specific for myocarditis, they are...
widely available and easier to obtain than most other cardiac tests. Thus, they are often useful as an early diagnostic study in the evaluation for suspected ICI-induced myocarditis. In a case control study, troponin T was elevated in 94% and NT-proBNP was elevated in 66% of ICI-induced myocarditis cases.\textsuperscript{21} In a separate case series, troponin I was elevated in 46% of cases, and BNP or N-terminal proBNP levels were elevated in 100% of cases.\textsuperscript{29} The level of troponin increase may depend on the timing of measurement as well as the severity of myocardial injury.\textsuperscript{43}

Currently, troponin is considered a marker for myocarditis however BNP is a marker of left ventricular (LV) dysfunction and acute cardiac stress. BNP has poor specificity as it may be elevated at baseline in cancer patients due to cancer-related inflammation.\textsuperscript{44} Cardiac troponin is commonly measured as troponin I or troponin T. Cardiac troponin T has been shown to occasionally be elevated from myositis. For this reason, troponin I may be helpful for correlating cardiac injury when overlap with myositis is present after ICI therapy.\textsuperscript{45}

The elevation of these biomarkers may also indicate a worse prognosis of the myocardial injury. In a case control study, the elevation of cardiac troponin T level was associated with a higher risk of CV AEs.\textsuperscript{21} Furthermore, the decrease in serum biomarkers may be helpful in following the clinical course of patients receiving anti-inflammatory treatment and heart failure therapy.\textsuperscript{46}

**Electrocardiogram**

Myocarditis may also cause disturbances of cardiac electrophysiology. When the inflammatory process reaches the conduction system, electrocardiographic changes may demonstrate intraventricular conduction delay, PR prolongation, or even advanced heart block.\textsuperscript{9} ICI-induced myocarditis may also present with many types of arrhythmias including atrial fibrillation and ventricular ectopy leading to ventricular tachycardia or fibrillation.\textsuperscript{29}

**Transthoracic echocardiogram**

ICI-associated cardiotoxicity may cause a reduction in the left ventricular ejection fraction (LVEF) which can account for approximately 46% of patients who develop myocarditis.\textsuperscript{47} Transthoracic echocardiography can reveal dilation of cardiac chambers, regional WMAs, or diffuse left-ventricular systolic dysfunction. However, a normal ejection fraction does not rule out ICI-associated myocarditis. Preservation of normal cardiac chamber sizes may be indicative of an acute process, while remodeling and dilatation may represent a subacute or chronic process.

Speckle tracking has also been used to monitor cardiotoxicity in cancer patients receiving various treatments. Although global longitudinal strain (GLS) use in ICI therapy is limited, in a recent case control series, 101 cases with ICI myocarditis were found to have decreased GLS (14.1 to ±2.8) compared to 92 control subjects who received ICI but didn’t develop myocarditis. In cases of both preserved or reduced LVEF, GLS was lower among confirmed myocarditis cases.\textsuperscript{48}

**Cardiac magnetic resonance imaging and fluorodeoxyglucose-positron emission tomography computed tomography**

When available, CMR is more sensitive than echocardiography for the detection of myocarditis as it provides tissue characterization with precise criteria for the diagnosis of myocarditis.\textsuperscript{49} The updated Lake Louise Criteria can be used to diagnose myocarditis if one of the main criteria or two supportive criteria are positive.
The main criteria include evidence of myocardial edema (either by regional elevated values by T2-mapping or high signal in T2-weighted images) or evidence of non-ischemic myocardial injury (either by regional elevated values by T1 mapping or presence of late gadolinium enhancement [LGE]). Supportive criteria include signs of pericarditis or systolic dysfunction with regional or global WMAs, although most cases maintain a preserved LVEF. Having both main criteria increase specificity, and in our institution, we require both to diagnose ICI-associated myocarditis with CMR.

A potential limitation of CMR lies in its sensitivity to detect ICI-associated myocarditis. In a case control study, CMR was able to detect myocardial edema in only one-third of cases. This was also shown in an international registry study, where the absence of LGE did not exclude ICI-associated myocarditis when compared to histological findings in endomyocardial biopsies. Also, presence of LGE did not predict cardiovascular outcomes in patients with confirmed ICI-associated myocarditis by biopsy.

When CMR is not available or contraindicated, a cardiac FDG-PET-CT may be performed to assess myocardial inflammation. The patient must be able to be on a high fat-low carbohydrate diet prior to the FDG-PET-CT for optimal imaging preparation. FDG-PET-CT findings may improve the sensitivity for mild or border line myocarditis and increase specificity for chronic myocarditis. If a CMR (or FDG-PET-CT) is positive for myocarditis, diagnosis may be sufficient to proceed with treatment, but if the study is negative for myocarditis, the next step in the diagnostic pathway should be an endomyocardial biopsy.

Endomyocardial biopsy

Aside from autopsy, EMB is considered the gold-standard procedure to diagnose ICI-associated myocarditis. Given its invasive approach, it should be performed at high volume centers with experienced operators and interpretation of results performed by pathologists familiar with diagnosing myocarditis and/or heart transplant rejection. Pathologic diagnosis of myocarditis may be made based upon the Dallas criteria. Definite myocarditis is demonstrated with the presence of inflammatory cells in the myocardium with necrosis and/or degeneration of adjacent myocytes. Borderline myocarditis may be diagnosed when the infiltrate is sparse, or myocyte injury is not present. In a study of 38 cases of autopsy proven myocarditis, the sensitivity and specificity of EMB were 60 and 80%, respectively. The sensitivity of EMB may be limited due to the focal and transient nature of inflammatory cell infiltrates. Due to the patchy nature of inflammatory infiltrates, obtaining multiple samples (≥4) is recommended when performing EMB from either a right ventricular or LV approach. With this understanding, EMB results should be corroborated with clinical suspicion and other diagnostic tests such as CMR.

In a series of 35 cases with ICI-associated myocarditis, 11 had a cardiac biopsy or autopsy. Findings demonstrated patchy and diffuse lymphocyte infiltration within the myocardium with histopathologic findings of T cells, mainly CD4+ and CD8+, with mild to moderate fibrosis in the areas of inflammation. PD-L1 staining was positive on the membrane of cardiomyocytes however it is unknown whether PD-L1 staining is specific for ICI induced myocarditis or present in other forms of cardiac injury as well. Of note, there were no granulomas or giant cells as would be observed in acute allograft rejection after cardiac transplantation.
MANAGEMENT

The management of ICI-associated cardiotoxicity begins with early hemodynamic stabilization and symptom mitigation. ICI cessation should be considered based on the type and severity of the CVAE. Steroids should be administered as first line therapy for most moderate-to-severe ICI-associated cardiotoxicity to alleviate the hyperactive T cell-associated immune response (Figure 2).

In ICI-associated myocarditis, ICI treatment should be discontinued to minimize morbidity and mortality. High-dose corticosteroids should be administered as recommended by the ASCO/National Cancer Control Network (NCCN) guidelines. Patients should start 1–2 mg/kg of prednisone, intravenously or orally. In severe or refractory cases 500–1,000 mg of intravenous methylprednisolone daily may be administered. Upon clinical stabilization, treatment is completed with oral prednisolone at 1 mg/kg daily tapered over 4–6 weeks. We recommend the same approach for patients presenting with myopericarditis, which has been shown to be efficacious in limited reports.

Second line treatments for steroid refractory patients include infliximab, anti-thymocyte globulin (ATG), tacrolimus, intravenous immunoglobulin (IVIG), plasmapheresis, and mycophenolate mofetil (MMF). However, the efficacy of these treatments is primarily illustrated in anecdotal reports and not corroborated through controlled studies.

Infliximab is a chimeric monoclonal antibody that binds to and neutralizes tumor necrosis factor-α, a key cytokine that modulates the body's immune response. For this reason, Infliximab is often utilized in a variety of autoimmune diseases, as well as ICI-associated

---

**Figure 2.** Treatment algorithm of ICI-associated cardiotoxicity by symptom type.

ACC = American College of Cardiology; AHA = American Heart Association; ICI = immune checkpoint inhibitor.

*Insufficient evidence to support safety of rechallenging ICI therapy. †Secondary treatments include: infliximab (not to be used in moderate to severe heart failure), anti-thymocyte globulin, mycophenolate mofetil, tacrolimus, intravenous immunoglobulin, plasmapheresis.
colitis and pneumonitis. Recent reports document successful use in myocarditis, but physicians should be wary of its contraindications in moderate-to-severe heart failure (NYHA III-IV) at doses greater than 5 mg/kg which have been associated with increased hospitalizations, morbidity, and death.7576

ATG and tacrolimus are commonly used treatments in cardiac allograft rejection that have been repurposed for use in ICI-associated myocarditis. ATG is an animal derived antibody that directly targets human T cells, while tacrolimus inhibits calcineurin, a molecule that promotes development of T cells. Some cases of ICI-associated myocarditis have shown some benefit with the addition of ATG or tacrolimus as second line treatments with steroids. As in cardiac allograft rejection they are believed to deplete multifocal lymphocytic and histiocytic infiltrates.5960

IVIG is derived from the plasma of human donors and treats inflammatory disorders through the interaction of the exogenous antibodies with the recipient’s immune pathways. The immunoglobulins are thought to act through a combination of T/B cell, complement pathway, cytokine and Fc Receptor inhibition. IVIG has had some success as second line therapy in both early and late onset ICI-associated myocarditis, with improvement of reduced ejection fraction, new arrhythmias and WMAs.63-66 Although steroid monotherapy continues to be the most common initial treatment, some reports using the initial combination of steroids and IVIG has been shown to be well tolerated for patients with mild-to-moderate myocarditis.63

Plasmapheresis may be used after failure of IVIG therapy or may be started as its own second line therapy following steroid treatment failure. Plasmapheresis is an extracorporeal treatment that selectively removes abnormal cells or substances in the blood. For ICI-associated myocarditis, this includes targets such as autoantibodies or the offending medications. In one case, serum levels of Pembrolizumab were shown to drop from 10,200ng/mL to 3340ng/mL after 2 cycles of plasma exchange.68 This is owed to the fact that antibodies, such as Pembrolizumab, are excellent targets as they are primarily intravascularly distributed in the body. This treatment has produced recovery of baseline cardiac function in several reported cases.68-72

Interestingly, initiation of steroids and IVIG or plasmapheresis may be strongly considered when patients present with a combination of myasthenia gravis, myositis and myocarditis. These constellation of immune events are quite common in ICI-associated myocarditis, with patients often presenting with ptosis, muscle weakness, and elevated troponins.64-67707779 In the overlap of these symptoms, patients have benefited receiving steroids with either IVIG or plasmapheresis on presentation.6970 Rituximab, a monoclonal antibody which targets the CD20 surface antigen of B cells, is another treatment which may also be useful in myocarditis patients presenting with myasthenia gravis. In a small case series it was shown to be effective in six of nine patients presenting with ICI-associated myasthenia gravis.70 Thus, rituximab may be a preferred secondary treatment option in ICI-associated myocarditis patients presenting with myasthenia gravis.

Re-initiation of ICI therapy is generally not recommended for ICI-associated myocarditis. For asymptomatic patients who have had complete clinical recovery, cardiologists and oncologists may consider rechallenging, but currently there is sparse data to support and guide these recommendations.
Treatment of other ICI-associated CVAEs including heart failure, acute coronary syndromes, arrhythmias and HTN may not require steroids and are centered around conventional cardiac therapy. ICI-associated heart failure often occurs in the setting of myocarditis, such that treatment similarly begins with suspension of ICIs and management of ICI-associated myocarditis. Management of heart failure and acute coronary syndromes should follow guidelines outlined by the American College of Cardiology/American Heart Association (ACC/AHA). These include intravenous diuretics, inotropes, afterload reduction and guideline directed medical therapy (ACE-Is, angiotensin II receptor blockers, beta blockers, spironolactone) for heart failure. In steroid refractory patients, caution is again warranted with infliximab in patients with moderate-to-severe heart failure. For acute coronary syndromes or coronary spasm, urgent cardiac catheterization with percutaneous intervention and anti-thrombotic therapy may be indicated.

Treatment of ICI-associated arrhythmias also begins with suspension of ICIs. Permanent cessation of the ICI can be coordinated between the cardiologist and oncologist on a case-by-case basis, depending on the clinical severity and response to treatments. Otherwise, following the ACC/AHA guidelines for supraventricular and ventricular arrhythmias are indicated. Bradyarrhythmias and advanced atrioventricular blocks may require temporary or permanent pacemaker placement.

Lastly, new onset HTN can be generally managed with blood pressure medications in most patients. Given the unknown time course of HTN on prolonged ICI therapy, the established blood pressure goals by age group are appropriate. However, if the blood pressure remains stable without end-organ damage, cessation of ICI therapy is generally not required in these patients. Steroids can be administered in both ICI-associated arrhythmias and HTN if symptoms are resistant to maximal therapy or signs of end-organ injury occur.

**EMERGING THERAPIES**

New targeted therapies under investigation include CTLA-4 agonists (abatacept) and CD52 antibodies (alemtuzumab). CTLA-4 agonists negate the immunostimulatory effects of PD-1, PDL1 and CTLA-4 inhibition by decreasing CD28/B7 T cell co-stimulation upstream. Abatacept is more commonly used in rheumatologic disease but targeting this pathway in ICI-associated myocarditis has been shown to be effective in animal studies and limited human case reports. Mouse models of ICI-associated myocarditis had significant decreases in myocardial immune infiltrates to near baseline after 14 weeks of treatment with abatacept. These mice also had significant mortality reduction compared to the untreated control group. Two case reports have described abatacept use in fulminant refractory ICI-associated myocarditis. The first case prescribed abatacept following the failure of steroids and MMF, while the other case used steroids and plasmapheresis. Due to lack of treatment response in both cases, abatacept was administered resulting in significant improvement of troponin levels, ventricular hyperexcitability and myositis symptoms (muscle weakness, facial paralysis). Abatacept is also well tolerated. A controlled trial (n=3,210) of abatacept in rheumatoid arthritis found 51.8% adverse events in the treatment group vs. 46.4% in the placebo group. The most frequent reported side effects were headache, nausea, and upper respiratory tract infections, leading to discontinuation in 3.3% of abatacept treated patients vs. 2.0% of placebo treated patients. Of note, all biological disease-modifying anti-rheumatic drugs (bDMARDs) carry a low risk of malignancy which can be of some concern.
to oncologists (0.22% incidence rate during treatment), however, abatacept has not been associated with an overall increased risk of cancer compared to other bDMARDs. Analyses by specific cancer type did show an increased odds ratio for melanoma (1.58 [95% confidence interval, 1.17–2.08]) when compared to other bDMARDs.\(^{[90]}\)

Another potential treatment that has been investigated for use in ICI myocarditis is Alemtuzumab, a CD52 monoclonal antibody that activates complement pathways of T cell depletion. It is effective in treatment of refractory transplant myocarditis which shows similar histopathological features of lymphocytic infiltration as found in ICI-associated myocarditis.\(^{[91]}\) In a case report of treatment resistant ICI-associated myocarditis,\(^{[76]}\) a 71-year-old woman presenting with myositis - myasthenia gravis syndrome and myocarditis received methylprednisolone, MMF, plasmapheresis and rituximab which failed to clinically improve her condition. Alemtuzumab was given as a single dose, resulting in resolution of her cardiac arrhythmias, ventricular dysfunction and abnormal lab findings. Given its limited reported use in ICI-associated myocarditis treatment, additional clinical trials will be needed to characterize efficacy and adverse events. In the interim, all second line treatments should be closely monitored for potential side effects including worsening heart failure, increased risk of infection and tumor growth.\(^{[92]}\)

**SURVEILLANCE**

There is currently no unified approach in monitoring patients starting ICI therapy. Recommended surveillance strategies have been proposed utilizing best available data. For example, ECG and troponin monitoring of 76 patients on combination ipilimumab and nivolumab by Lee Chuy et al.\(^{[93]}\) was not able to detect any myocarditis. However, in patients whom physicians suspect higher risk or greater clinical consequences of myocarditis, case-by-case evaluation for surveillance is reasonable. Johnson et al suggests a baseline ECG and weekly testing of troponin levels during weeks 1 to 3 for patients receiving combination immunotherapy.\(^{[9]}\) In the majority of patients receiving ICIs who have normal baseline ECG and LVEF prior to treatment, clinical education and monitoring of symptoms is a reasonable approach. The surveillance for high risk patients may include more frequent echocardiogram monitoring for changes in LV function and/or strain, especially in patients with an abnormal LV function at baseline.\(^{[94]}\) We have proposed a surveillance strategy for patients initiating ICI therapy as seen in Figure 3. With the increased use of ICI therapy, better monitoring and risk stratification will be needed to determine patients suitable for increased surveillance.

Less severe side effects, such as HTN, may not require monitoring outside of routine clinic visits and home blood pressure measurements. Upon development of symptoms, more extensive workup as outlined above is carried out and directed by a consultant cardiologist.

**PROGNOSIS**

In contrast to its low incidence, ICI-associated myocarditis has generally been associated with high rates of morbidity and mortality. Data from the Bristol-Myers Squibb registry reported a mortality rate of 33%\(^{[9]}\). A multicenter registry reported that 46% of patients diagnosed with myocarditis experienced a MACE, defined as the composite of cardiovascular death, cardiogenic shock, cardiac arrest and hemodynamically significant complete heart
This was supported in another study from the WHO database which also reported a mortality rate of 46% in all cases of severe ICI-associated myocarditis.

CONCLUSION

ICI cardiotoxicity is a rare but potentially lethal complication of cancer immunotherapy. Despite the growing use of ICI treatments, our recognition of CVAEs remains based upon clinical suspicion and diagnostic tests with limited sensitivity. Risk factors such as DM, OSA, and a high BMI have shown potentially worse outcomes with ICI-associated myocarditis. Further translational research into the mechanisms of myocardial injury is needed to better identify more specific biomarkers for diagnosis.

Screening and surveillance of patients is crucial prior to ICI therapy. Clinicians should promptly recognize new symptoms and initiate workup based on the type and severity of the adverse effects. Currently available cardiac biomarkers and imaging are helpful in establishing diagnosis but exhibit low sensitivity and may often warrant invasive testing with an endomyocardial biopsy for confirmation. Prompt treatment is centered around high dose corticosteroids with second line therapies being reserved for patients refractory to steroids.

ICI-associated CVAE diagnosis and management is challenging, often requiring expert consultation from those familiar with cardio-oncology practice. Although current guidelines are based on expert opinion and limited case series, investigations are ongoing to establish best practice. Until then, it is important for clinicians to understand the common clinical syndromes of ICI-associated myocarditis and surveillance strategies for monitoring patients receiving ICI therapy. With increased familiarity and education, cardiologists and oncologists can work together to safely deliver what has become the standard of care treatment for previously untreatable advanced malignancies.

---

**Figure 3. Surveillance and Evaluation of ICI cardiotoxicity.**

ECG = electrocardiography; FDG = fluorodeoxyglucose; ICI = immune checkpoint inhibitor; LVEF = left ventricular ejection fraction; MRI = magnetic resonance imaging; NT pro-BNP = N-terminal pro B-type natriuretic peptide; PET/CT = positron emission tomography/computed tomography; TnI = troponin I.

*Patients with diabetes mellitus, obstructive sleep apnea, elevated body mass index, abnormal LVEF on baseline echocardiography, previous cardiovascular disease or combination therapy (including chemotherapy with cardiovascular side effect).
REFERENCES

1. Chang CF. Disease and its impact on politics, diplomacy, and the military: the case of smallpox and the Manchus (1613–1795). J Hist Med Allied Sci 2002;57:177-97.

2. McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J 2006;26:154-8.

3. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014;130:2071-104.

4. Tarrio ML, Grabie N, Bu DX, Sharpe AH, Lichtman AH. PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J Immunol 2012;188:4876-84.

5. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3:541-7.

6. Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001;291:319-22.

7. Xi C, Roy MD, Golas J, et al. Myocarditis in cynomolgus monkeys following treatment with immune checkpoint inhibitors. Clin Cancer Res 2019;25:4735-48.

8. Heiznerling L, Ott PA, Hodi FS, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer 2016;4:90.

9. Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016;375:1749-55.

10. Bu DX, Tarrio M, Maganto-Garcia E, et al. Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation. Arterioscler Thromb Vasc Biol 2011;31:1100-7.

11. Foks AC, Kuiper J. Immune checkpoint proteins: exploring their therapeutic potential to regulate atherosclerosis. Br J Pharmacol 2017;174:3940-55.

12. Lee J, Zhuang Y, Wei X, et al. Contributions of PD-1/PD-L1 pathway to interactions of myeloid DCs with T cells in atherosclerosis. J Mol Cell Cardiol 2009;46:169-76.

13. Tomiyama H, Shiina K, Matsumoto-Nakano C, et al. The contribution of inflammation to the development of hypertension mediated by increased arterial stiffness. J Am Heart Assoc 2017;6:e005729.

14. Tadokoro T, Keshino E, Makiyama A, et al. Acute lymphocytic myocarditis with anti-PD-1 antibody nivolumab. Cite Heart Fail 2016;9:e003514.

15. Läubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer 2015;3:11.

16. Tajmir-Riahi A, Bergmann T, Schmid M, Agaimy A, Schuler G, Heiznerling L. Life-threatening autoimmune cardiomyopathy reproducibly induced in a patient by checkpoint inhibitor therapy. J Immunother 2018;41:35-8.

17. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018;36:1714-68.

18. Jain V, Bahia J, Mohebtash M, Barac A. Cardiovascular complications associated with novel cancer immunotherapies. Curr Treat Options Cardiovasc Med 2017;19:36.
19. Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 2018;71:1755-64.

20. Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 2016;60:210-25.

21. Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 2018;71:1755-64.

22. Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 2018;19:1579-89.

23. Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 2018;391:933.

24. Amiri-Kordestani L, Moslehi J, Cheng J, et al. Cardiovascular adverse events in immune checkpoint inhibitor clinical trials: a U.S. Food and Drug Administration pooled analysis. J Clin Oncol 2018;36(15 Suppl):3009.

25. Palaskas N, Morgan J, Daigle T, et al. Targeted cancer therapies with pericardial effusions requiring pericardiocentesis focusing on immune checkpoint inhibitors. Am J Cardiol 2019;123:1351-7.

26. Kolla BC, Patel MR. Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy - a report of two cases. J Immunother Cancer 2016;4:80.

27. Khan A, Zhang H, Chen C, et al. Impact of pericardial effusion for patients receiving immune checkpoint inhibitors. J Clin Oncol 2019;37(15 Suppl):e14121.

28. Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013;34:2636–48.

29. Escudier M, Cautela J, Salem JE, et al. Acute coronary syndrome with immune checkpoint inhibitors: a proof-of-concept case and pharmacovigilance analysis of a life-threatening adverse event. Can J Cardiol 2020;36:476-81.

30. Nykl R, Fischer O, Vykoupil K, Taborsky M. A unique reason for coronary spasm causing temporary ST elevation myocardial infarction (inferior STEMI) - systemic inflammatory response syndrome after use of pembrolizumab. Arch Med Sci Atheroscler Dis 2017;2:e100-2.

31. Lyon AR, Yousaf N, Battisti NM, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Circulation 2017;136:2085-7.

32. Mirabel M, Karapetiantz P, Marijon E, et al. The risk of sudden cardiac death or ventricular arrhythmias on immune checkpoint inhibitors. Eur Heart J 2020;41 Suppl 2:ehaa946.3488.

33. Cautela J, Rouby F, Salem JE, et al. Acute coronary syndrome with immune checkpoint inhibitors: a proof-of-concept case and pharmacovigilance analysis of a life-threatening adverse event. Can J Cardiol 2020;36:476-81.

34. Lyss P, Fischer O, Vykoupil K, Taborsky M. A unique reason for coronary spasm causing temporary ST elevation myocardial infarction (inferior STEMI) - systemic inflammatory response syndrome after use of pembrolizumab. Arch Med Sci Atheroscler Dis 2017;2:e100-2.

35. Lyon AR, Yousaf N, Battisti NM, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Circulation 2017;136:2085-7.

36. Hui R, Garon EB, Goldman JW, et al. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Ann Oncol 2017;28:874-81.
37. Mok TS, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. *Lancet* 2019;393:1819-30.

38. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet* 2016;387:1540-50.

39. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. *N Engl J Med* 2016;375:1823-33.

40. Chen J, Hu X, Li Q, et al. Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients. *Ann Transl Med* 2020;8:1187.

41. de Azevedo SJ, de Melo AC, Roberts L, Caro I, Xue C, Wainstein A. First-line atezolizumab monotherapy in patients with advanced BRAF**V600** wild-type melanoma. *Pigment Cell Melanoma Res*. 2021 [Epub ahead of print].

42. Lee MS, Ryoo BY, Hsu CH, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. *Lancet Oncol* 2020;21:808-20.

43. Massin M, Crochelet AS, Jacquemart C. Acute myocarditis with very high troponin but no ventricular dysfunction. *Clin Pediatr (Phila)* 2017;56:582-3.

44. Bando S, Soeki T, Matsuura T, et al. Plasma brain natriuretic peptide levels are elevated in patients with cancer. *PLoS One* 2017;12:e0178607.

45. Hughes M, Lilleker JB, Herrick AL, Chinoy H. Cardiac troponin testing in idiopathic inflammatory myopathies and systemic sclerosis-spectrum disorders: biomarkers to distinguish between primary cardiac involvement and low-grade skeletal muscle disease activity. *Ann Rheum Dis* 2015;74:795-8.

46. Alvarez-Cardona Jose A, Zhang Kathleen W, Mitchell Joshua D, Zaha Vlad G, Fisch Michael J, Lenihan Daniel J. Cardiac biomarkers during cancer therapy. *JACC CardioOncol* 2020;2:791-4.

47. Kindermann I, Kindermann M, Kandolf R, et al. Predictors of outcome in patients with suspected myocarditis. *Circulation* 2008;118:639-48.

48. Awdadallah M, Mahmood SS, Groatke JD, et al. Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis. *J Am Coll Cardiol* 2020;75:467-78.

49. Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. *J Am Coll Cardiol* 2018;72:3158-76.

50. Zhang L, Awdadallah M, Mahmood SS, et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. *Eur Heart J* 2020;41:1733-43.
56. Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. *J Am Heart Assoc* 2020;9:e013757.

57. Saade A, Mansuet-Lupo A, Arrondeau J, et al. Pericardial effusion under nivolumab: case-reports and review of the literature. *J Immunother Cancer* 2019;7:266.

58. Frigeri M, Meyer P, Banfi C, et al. Immune checkpoint inhibitor-associated myocarditis: a new challenge for cardiologists. *Can J Cardiol* 2018;34:92.e1-3.

59. Tay RY, Blackley E, McLean C, et al. Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy. *Br J Cancer* 2017;117:921-4.

60. Jain V, Mohebtash M, Rodrigo ME, Ruiz G, Atkins MB, Barac A. Autoimmune myocarditis caused by immune checkpoint inhibitors treated with antithymocyte globulin. *J Immunother* 2018;41:332-5.

61. Wang DY, Okoye GD, Neilan TG, Johnson DB, Moslehi JJ. Cardiovascular toxicities associated with cancer immunotherapies. *Curr Cardiol Rep* 2017;19:21.

62. Cafferio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. *Eur Heart J* 2013;34:2636-48.

63. Balanescu DV, Donisian T, Palaskas N, et al. Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: pathway toward precision-based therapy. *Cardiovasc Pathol* 2020;47:107211.

64. Yamaguchi S, Morimoto R, Okumura T, et al. Late-onset fulminant myocarditis with immune checkpoint inhibitor nivolumab. *Can J Cardiol* 2018;34:812.e1-3.

65. Xing Q, Zhang ZW, Lin QH, et al. Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma. *Ann Transl Med* 2020;8:250.

66. Yanase T, Moritoki Y, Kondo H, Ueyama D, Akita H, Yasui T. Myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma: a case report of successful management. *Urol Case Rep* 2020;34:101508.

67. Fazel M, Jedlowski PM. Severe myositis, myocarditis, and myasthenia gravis with elevated anti-striated muscle antibody following single dose of ipilimumab-nivolumab therapy in a patient with metastatic melanoma. *Case Reports Immunol* 2019;2019:2539493.

68. Yogasundaram H, Alhumaid W, Chen JW, et al. Plasma exchange for immune checkpoint inhibitor-induced myocarditis. *CJC Open* 2020;3:379-82.

69. Compton F, He L, Sarode R, et al. Immune checkpoint inhibitor toxicity: a new indication for therapeutic plasma exchange? *J Clin Apher* 2021;jca.21890.

70. Schiopu SR, Käsmann L, Schönerrmack U, et al. Pembrolizumab-induced myocarditis in a patient with malignant mesothelioma: plasma exchange as a successful emerging therapy-case report. *Transl Lung Cancer Res* 2021;10:1039-46.

71. Kimura T, Fukushima S, Miyashita A, et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab. *Cancer Sci* 2016;107:1055-8.

72. Rota E, Varese P, Agosti S, et al. Concomitant myasthenia gravis, myositis, myocarditis and polyneuropathy, induced by immune-checkpoint inhibitors: a life-threatening continuum of neuromuscular and cardiac toxicity. *eNeurologicalSci* 2018;14:4-5.

73. Reddy N, Moudgil R, Lopez-Mattei JC, et al. Progressive and reversible conduction disease with checkpoint inhibitors. *Can J Cardiol* 2017;33:1335.e13-5.
74. Hu JR, Florido R, Lipson EI, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. *Cardiovasc Res* 2019;115:854-68.

75. Kwon HI, Coté TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. *Ann Intern Med* 2003;138:807-11.

76. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. *Circulation* 2003;107:3133-40.

77. Jeyakumar N, Etchegary M, Henry J, et al. The terrible triad of checkpoint inhibition: a case report of myasthenia gravis, myocarditis, and myositis induced by cemiplimab in a patient with metastatic cutaneous squamous cell carcinoma. *Case Reports Immunol* 2020;2020:5126717.

78. Esfahani K, Buhlaiqa N, Thébault P, Lapointe R, Johnson NA, Miller WH Jr. Alemtuzumab for immune-related myocarditis due to PD-1 therapy. *N Engl J Med* 2019;380:2375-6.

79. Deftereos SN, Georgonikou D. Effectiveness of rituximab in treating immune-checkpoint-inhibitor-induced immune-related adverse events: results of a systematic review. *Ann Oncol* 2021;32:282-3.

80. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *Circulation* 2017;136:e137-61.

81. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2014;64:e139-228.

82. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). *Circulation* 2004;110:588-636.

83. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Heart Rhythm* 2018;15:e190-252.

84. Behling J, Kaes J, Münzel T, Grabbe S, Loquai C. New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma. *Melanoma Res* 2017;27:155-8.

85. Ingelfinger JR, Schwartz RS. Immunosuppression--the promise of specificity. *N Engl J Med* 2005;353:836-9.

86. Wei SC, Meijers WC, Axelrod ML, et al. A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention. *Cancer Discov* 2021;11:614-25.

87. Liu S, Chan I, Brinc D, et al. Immune checkpoint inhibitor-associated myocarditis with persistent troponin elevation despite abatacept and prolonged immunosuppression. *JACC CardioOncol* 2020;2:800-4.

88. Salem IE, Allenbach Y, Vozy A, et al. Abatacept for severe immune checkpoint inhibitor-associated myocarditis. *N Engl J Med* 2019;380:2377-9.

89. Blair HA, Deeks ED. Abatacept: a review in rheumatoid arthritis. *Drugs* 2017;77:1221-33.
90. Simon TA, Boers M, Hochberg M, et al. Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study. *Arthritis Res Ther* 2019;21:228.

91. Chen DY, Huang WK, Chien-Chia Wu V, et al. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: a review when cardiology meets immuno-oncology. *J Formos Med Assoc* 2020;119:1461-75.

92. Zhou YW, Zhu YJ, Wang MN, et al. Immune checkpoint inhibitor-associated cardiotoxicity: current understanding on its mechanism, diagnosis and management. *Front Pharmacol* 2019;10:1350.

93. Lee Chuy K, Oikonomou EK, Postow MA, et al. Myocarditis surveillance in patients with advanced melanoma on combination immune checkpoint inhibitor therapy: The Memorial Sloan Kettering Cancer Center experience. *Oncologist* 2019;24:e196-7.

94. Lyon AR, Yousaf N, Battisti NM, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. *Lancet Oncol* 2018;19:e447-58.